港鐵(00066.HK)高鐵香港段7月起新增三個新站連接四川省長途線 每日南北各一班車
港鐵(00066.HK)宣布,高鐵香港段將於7月起增設連接四川省長途線,三個新站點分別為成都東、樂山及宜賓西,每日提供南、北行各一班列車服務。乘客最快本周六(17日)起可購買7月1日的列車班次車票。
因應今次服務提升,加上個別站點的列車班次亦作輕微調整,高鐵網絡覆蓋將遍及全國69個站點,列車服務由每日164班,增至182班,每天短途列車服務將達到146班。
而往來香港西九龍站與廣州東站、深圳北站及福田站的列車服務亦會由同日起加強,每日往返廣州東站的列車班次由13班增加至19班,往返深圳北站的班次則會由49班增至51班,往返福田站的班次則會由30班增至38班。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.